RNAC vs. ANIP, DYN, INDV, AMPH, ARDX, EVO, ETNB, OCUL, GPCR, and IOVA
Should you be buying Cartesian Therapeutics stock or one of its competitors? The main competitors of Cartesian Therapeutics include ANI Pharmaceuticals (ANIP), Dyne Therapeutics (DYN), Indivior (INDV), Amphastar Pharmaceuticals (AMPH), Ardelyx (ARDX), Evotec (EVO), 89bio (ETNB), Ocular Therapeutix (OCUL), Structure Therapeutics (GPCR), and Iovance Biotherapeutics (IOVA). These companies are all part of the "pharmaceutical products" industry.
Cartesian Therapeutics vs.
ANI Pharmaceuticals (NASDAQ:ANIP) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, community ranking, institutional ownership, analyst recommendations, risk, earnings and profitability.
76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.9% of Cartesian Therapeutics shares are owned by institutional investors. 12.7% of ANI Pharmaceuticals shares are owned by company insiders. Comparatively, 57.9% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
ANI Pharmaceuticals has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500.
In the previous week, ANI Pharmaceuticals and ANI Pharmaceuticals both had 7 articles in the media. Cartesian Therapeutics' average media sentiment score of 1.08 beat ANI Pharmaceuticals' score of 1.04 indicating that Cartesian Therapeutics is being referred to more favorably in the news media.
ANI Pharmaceuticals received 403 more outperform votes than Cartesian Therapeutics when rated by MarketBeat users. However, 94.74% of users gave Cartesian Therapeutics an outperform vote while only 64.46% of users gave ANI Pharmaceuticals an outperform vote.
ANI Pharmaceuticals has higher revenue and earnings than Cartesian Therapeutics. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.
ANI Pharmaceuticals has a net margin of -1.28% compared to Cartesian Therapeutics' net margin of -510.72%. ANI Pharmaceuticals' return on equity of 15.87% beat Cartesian Therapeutics' return on equity.
ANI Pharmaceuticals currently has a consensus target price of $79.75, suggesting a potential upside of 20.23%. Cartesian Therapeutics has a consensus target price of $42.14, suggesting a potential upside of 164.72%. Given Cartesian Therapeutics' higher probable upside, analysts clearly believe Cartesian Therapeutics is more favorable than ANI Pharmaceuticals.
Summary
ANI Pharmaceuticals and Cartesian Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get Cartesian Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cartesian Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:RNAC) was last updated on 3/26/2025 by MarketBeat.com Staff
Buy RNAC Stock Free RNAC Stock Alerts